Abera and Intravacc combine forces; first TKI funded project launched at Intravacc.
The Dutch Life Sciences & Health (LSH) sector is one of nine “top sectors” in the Netherlands. To achieve their mission of ‘vital citizens in a healthy economy’ the top sector LSH initiates and stimulates multidisciplinary public private partnership (PPP) to valorize innovation. Within Intravacc the first TKI funded project is a collaboration with the Swedish biotech company Abera that has developed a vaccine platform for the secretion and surface display of heterologous proteins by Gram-negative bacteria based on the Escherichia coli autotransporter Hemoglobin protease (Hbp).
In this collaboration, the know-how of Intravacc on efficient production of OMVs derived from Neisseria meningitidis that have proven safe and are already accepted for human use will be combined with the Hbp autotransporter system as a tool for high-density surface display of antigens from bacteria for which antibiotic resistance is becoming a serious problem. In the current project antigens from Mycobacterium tuberculosis and Acinetobacter baumannii will be expressed in Neisseria outer membrane vesicles, as a novel approach for the development of vaccines against tuberculosis and multi-drug resistant infections, respectively.